Respiratory
Shavit A, Dolin P, Kielar D, Keogh KA, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen SY. Pulmonary involvement and persistent pulmonary damage in eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American Thoracic Society (ATS) 2024 Meeting; May 19, 2024. San Diego, CA.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.
INTRODUCTION & OBJECTIVE: Older adults and adults with comorbidities, such as metabolic diseases, are at increased risk of severe respiratory syncytial virus (RSV) disease. This study assessed the cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults 50-59 years of age (YOA) with diabetes in the US.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
OBJECTIVES: Older adults and adults with chronic cardiopulmonary diseases are at increased risk of severe respiratory syncytial virus (RSV) disease. This study examined the cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults 50-59 years of age (YOA) with select cardiopulmonary diseases.
La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S138. doi: 10.1016/j.jval.2024.03.738
OBJECTIVES Value of vaccination analyses often use assumptions or dated estimates from published literature for work loss associated with vaccine administration. This study evaluates work loss among adults recently vaccinated in pharmacies or healthcare professional (HCP) offices in the United States (US).
Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Apr;13(4):827-44. doi: 10.1007/s40121-024-00939-w
INTRODUCTION: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality.
La E, Verelst F, Curran D, Poston S, Graham J, Molnar D. Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults AGED ≥60 years in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
BACKGROUND: Cardiopulmonary disease is associated with an increased risk of severe respiratory syncytial virus (RSV) disease in adults. This study estimated the potential public health impact of adjuvanted RSVPreF3 vaccination in adults 50-59 years of age (YOA) with select cardiopulmonary diseases in the United States (US).
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
BACKGROUND: Adults with chronic cardiopulmonary conditions are at increased risk of severe respiratory syncytial virus (RSV) disease. This study estimated the burden of RSV in adults 50-59 years of age (YOA) with chronic cardiopulmonary diseases in the United States (US).